Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

ClinicalTrials.gov ID: NCT04115319

Public ClinicalTrials.gov record NCT04115319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.

Study identification

NCT ID
NCT04115319
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
305 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 20, 2019
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Last update posted
Dec 30, 2025

2019 – 2022

United States locations

U.S. sites
18
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
Research Site Cerritos California 90703
Research Site Oakland California 94607
Research Site Oceanside California 92056
Research Site San Diego California 92103
Research Site Torrance California 90502
Research Site Miami Florida 33122
Research Site Miami Lakes Florida 33016
Research Site Atlanta Georgia 30328
Research Site Hoffman Estates Illinois 60169
Research Site Lincolnwood Illinois 60712
Research Site Shreveport Louisiana 71101
Research Site St Louis Missouri 63128
Research Site Las Vegas Nevada 89102
Research Site Cedarhurst New York 11516
Research Site Jamaica New York 11432
Research Site Rochester New York 14618
Research Site Charlotte North Carolina 28211
Research Site North Canton Ohio 44720

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04115319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 30, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04115319 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →